1. Scrip
  2. >>Scrip Perspectives

Fewer Acquisitions And Alliances In 2023, But Valuations Increased

 
• By Joseph Haas

INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.

Scrip Perspectives 2023/2024: 2023 Deals Overview
In both M&A and alliances, 2023 saw lower deal volume but higher deal valuations • Source: Shutterstock

While Pfizer Inc.’s acquisition of Seagen Inc. in March did not set off a wave of mega-mergers, and overall deal volume was down in both mergers-and-acquisitions and alliances in 2023, the valuations did trend higher – even excluding the $43bn Pfizer/Seagen merger.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Perspectives

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Eleanor Malone

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

 
• By Eleanor Malone

Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.

M&A Takeoff May Be Delayed, Experts Predict

 
• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.

10 Clinical Trials To Look Out For In 2025

 
• By Alexandra Shimmings

Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.

More from Scrip

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

 
• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.